Clinical Report: Updated FDA-Approved ICI Combination Therapies as of July 2024
Overview
This correction updates the list of FDA-approved immune checkpoint inhibitor (ICI) combination therapies to include previously omitted regimens and reflects approvals current as of July 2024. It also clarifies the timing of pembrolizumab plus chemotherapy approval for non-small cell lung cancer (NSCLC).
Background
Immune checkpoint inhibitors have transformed cancer treatment, but resistance remains a significant challenge. Combination therapies involving ICIs and other agents such as chemotherapy have been developed to overcome resistance and improve outcomes. Accurate and up-to-date information on FDA-approved combinations is critical for guiding clinical decision-making.
Data Highlights
Combination Therapy
Indication
FDA Approval Status (as of July 2024)
Pembrolizumab + Chemotherapy
NSCLC
Approved
Other FDA-approved ICI combinations
Various cancers including TNBC, HNSCC, GEJ, ESCC, HCC, dMMR/MSI cancers, UC, RCC, CRC
Approved
Key Findings
Several FDA-approved ICI combination therapies were previously omitted and have now been included in the updated table.
The updated table comprehensively lists all FDA-approved ICI combinations as of July 2024.
The timing of pembrolizumab plus chemotherapy approval for NSCLC has been clarified to avoid misleading interpretation.
Combination therapies span multiple cancer types including NSCLC, triple-negative breast cancer, head and neck squamous cell carcinoma, and others.
Accurate documentation of FDA approvals supports informed clinical application of ICI combinations.
Clinical Implications
Clinicians should refer to the updated comprehensive list of FDA-approved ICI combination therapies to guide treatment selection. Awareness of the corrected timing of pembrolizumab plus chemotherapy approval for NSCLC ensures accurate understanding of therapeutic options. This update supports optimized management of patients with cancers responsive to ICI combinations.
Conclusion
The correction provides an accurate, up-to-date resource on FDA-approved ICI combination therapies, enhancing clinical guidance for overcoming resistance to immune checkpoint inhibitors. Maintaining current knowledge of approvals is essential for effective cancer immunotherapy.
